Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

Publication | Open Access

DOI Full Paper Access

571

Citations

References

2013

Year

Kevin Fitzgerald, Maria Frank-Kamenetsky, Svetlana Shulga‐Morskaya, Abigail Liebow, Brian R. Bettencourt, Jessica E. Sutherland, Renta Hutabarat, Valerie A. Clausen, Verena Karsten, Jeffrey Cehelsky,

The Lancet

Metabolic SyndromeOxysterolBiochemistryCardiovascular DiseaseHealthy VolunteersPharmacologyRna Interference DrugHyperlipidemiaSerum Ldl CholesterolMedicineAtherosclerosisDyslipidemia